Search results for "THROMBOEMBOLISM"

showing 10 items of 208 documents

Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomi…

2012

Background and objective: Thrombopoietin receptor (TPOr) agonists (romiplostim and eltrombopag) are a new approach for the treatment of thrombocytopenia-associated conditions. They promote megakaryocyte differentiation, proliferation and platelet production. In the European Union, both are orphan drugs with an indication restricted to splenectomized immune thrombocytopenic purpura patients who are refractory to other treatments. Due to increasing platelet counts, these drugs may represent a risk for thromboembolic complications. We analyzed whether TPOr agonists affect thromboembolisms occurrence in adult thrombocytopenic patients. Materials and methods: We conducted a systematic review and…

Adultmedicine.medical_specialtyMegakaryocyte differentiationRecombinant Fusion ProteinsEltrombopagReceptors FcBenzoateslaw.inventionchemistry.chemical_compoundRandomized controlled triallawRisk FactorsInternal medicineHematologic AgentsThromboembolismmedicinemedia_common.cataloged_instanceHumansEuropean unionmedia_commonRandomized Controlled Trials as TopicRomiplostimbusiness.industryGeneral MedicineNumber needed to harmThrombocytopeniaSurgeryHydrazineschemistryThrombopoietinMeta-analysisRelative riskPyrazolesbusinessReceptors Thrombopoietinmedicine.drugMedicina clinica
researchProduct

Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial …

2016

Summary Background Women with a history of venous thromboembolism (VTE) have a 2% to 10% absolute risk of VTE recurrence during subsequent pregnancies. Therefore, current guidelines recommend that all pregnant women with a history of VTE receive pharmacologic thromboprophylaxis. The optimal dose of low-molecular-weight heparin (LMWH) for thromboprophylaxis is unknown. In the Highlow study (NCT 01828697; www.highlowstudy.org ), we compare a fixed low dose of LMWH with an intermediate dose of LMWH for the prevention of pregnancy-associated recurrent VTE. We present the rationale and design features of this study. Methods The Highlow study is an investigator-initiated, multicentre, internation…

Adultmedicine.medical_specialtymedicine.drug_classPregnancy Complications CardiovascularLow molecular weight heparinHemorrhage030204 cardiovascular system & hematologylaw.inventionYoung Adult03 medical and health sciencesClinical trials0302 clinical medicineRandomized controlled trialRecurrencePregnancylawInternal medicineVenous thrombosisSecondary PreventionHumansMedicinecardiovascular diseasesPregnancy030219 obstetrics & reproductive medicineProphylaxisbusiness.industryPostpartum PeriodAbsolute risk reductionAnticoagulantsVenous ThromboembolismHematologyHeparinHeparin Low-Molecular-Weightmedicine.diseaseequipment and suppliesLMWHSurgeryClinical trialVenous thrombosisTreatment OutcomeGestationFemalebusinessmedicine.drug
researchProduct

Incidence and Clinical Impact of Right Ventricular Involvement (Biventricular Ballooning) in Takotsubo Syndrome: Results From the GEIST Registry

2021

Background: The short- and long-term prognosis of Takotsubo syndrome (TTS) presenting with right ventricular (RV) involvement remains poorly understood. Research Question: What is the incidence and clinical outcome of RV involvement in TTS? Study Design and Methods: This study analyzed 839 consecutive patients with TTS (758 female subjects and 81 male subjects) in a multicenter registry. RV involvement was defined as wall motion abnormality of the RV free wall, with or without apical involvement. The median long-term follow-up was 2.1 years (interquartile range, 0.3-4.5 years). The primary outcome was in-hospital and out-of-hospital all-cause mortality. The secondary end point was a composi…

Aged 80 and overMaleIncidenceVentricular Dysfunction Rightshort- and long-term outcomeShock CardiogenicArrhythmias CardiacPulmonary EdemaMiddle AgedPrognosisVentricular Dysfunction Leftright ventricular involvementTakotsubo CardiomyopathyThromboembolismHumansFemaleHospital MortalityRegistriesMortalityTakotsubo syndromeAged
researchProduct

Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study

2016

Background: Atrial fibrillation (AF) is associated with a substantial risk of thromboembolism and mortality, significantly reduced by oral anticoagulation. Adherence to guidelines may lower the risks for both all cause and cardiovascular (CV) deaths. Methods: Our objective was to evaluate if antithrombotic prophylaxis according to the 2012 European Society of Cardiology (ESC) guidelines is associated to a lower rate of adverse outcomes. Data were obtained from REPOSI; a prospective observational study enrolling inpatients aged ≥65 years. Patients enrolled in 2012 and 2014 discharged with an AF diagnosis were analysed. Results: Among 2535 patients, 558 (22.0 %) were discharged with a diagnos…

Antithrombotic therapy; Atrial fibrillation; Elderly; Guidelines; Outcomes; Cardiology and Cardiovascular MedicineMaleRegistrieTime Factorsantithrombotic therapy; atrial fibrillation; elderly; guidelines; outcomesAtrial fibrillation (AF)Practice PatternsKaplan-Meier Estimate030204 cardiovascular system & hematologyGuidelineoutcomesCoronary artery disease0302 clinical medicineElderlyRisk FactorsAtrial FibrillationAntithrombotic80 and overAge Factor030212 general & internal medicineRegistriesguidelinesAntithrombotic therapy Atrial fibrillation Elderly Guidelines OutcomesPractice Patterns Physicians'OutcomeAged 80 and overFibrinolytic AgentAge FactorsAtrial fibrillationGeneral MedicineTreatment OutcomeItalyAtrial fibrillation (AF) thromboembolism antithrombotic prophylaxisPractice Guidelines as TopicCardiologyFemaleGuideline AdherenceCardiology and Cardiovascular MedicineHumanAntithrombotic therapy; Atrial fibrillation; Elderly; Guidelines; Outcomes; Age Factors; Aged; Aged 80 and over; Atrial Fibrillation; Chi-Square Distribution; Female; Fibrinolytic Agents; Guideline Adherence; Humans; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Practice Patterns Physicians'; Proportional Hazards Models; Registries; Risk Assessment; Risk Factors; Thromboembolism; Time Factors; Treatment Outcome; Practice Guidelines as Topic; Cardiology and Cardiovascular Medicinemedicine.medical_specialtyLogistic ModelTime FactorSocio-culturaleLower riskRisk Assessment03 medical and health sciencesFibrinolytic AgentsInternal medicineThromboembolismmedicineHumansProportional Hazards ModelsAgedAntithrombotic therapyPhysicians'Chi-Square Distributionbusiness.industryProportional hazards modelRisk FactorSettore MED/09 - MEDICINA INTERNAGuidelinethromboembolismmedicine.diseaseAtrial fibrillationLogistic ModelsProportional Hazards Modelantithrombotic prophylaxisbusinessChi-squared distributionFibrinolytic agent
researchProduct

Potential of Multidimensional, Large-scale Biodatabases to Elucidate Coagulation and Platelet Pathways as an Approach towards Precision Medicine in T…

2019

Cardiovascular and especially thrombotic diseases remain a major cause of morbidity and mortality worldwide. In past years, significant improvements in understanding disease processes, risk assessment, and prediction of clinical outcome in the field of thrombosis and haemostasis have been made by using large-scale biodatabases. These important research resources enable a comprehensive research approach by integrating clinical, environmental, genomic, and molecular information. Cutting edge, high throughput technologies open new data dimensions for clinical large-scale investigations. Joining multiple information levels from several pathophysiological pathways in contrast to a single marker …

Blood Plateletsmedicine.medical_specialtyDatabases Factualbusiness.industryThrombosisHematologyDisease030204 cardiovascular system & hematologyDisease pathogenesisPrecision medicine03 medical and health sciences0302 clinical medicineCoagulationmedicineHumansPlateletThrombotic diseasePrecision MedicineRisk assessmentIntensive care medicinebusinessBlood CoagulationVenous thromboembolismBiomarkers030215 immunologyHämostaseologie
researchProduct

Enhanced platelet thromboxane synthesis and reduced macrophage-dependent fibrinolytic activity related to oxidative stress in oral contraceptive-trea…

1996

Abstract In previous studies conducted in rats and in women, we have shown that oral contraceptive (OC) administration induced a platelet hyperaggregation simultaneously with an increased platelet lipid biosynthesis which might be related to lipid peroxidation. In the present study, we specifically studied the arachidonic acid and the fibrinolytic pathways in relation to the fatty acid composition in female rats treated for 6 weeks with OC (ethinyl estradiol plus lynestrenol). We found that platelets of treated animals were not only hyper-responsive to thrombin and ADP, but also to sodium arachidonate. In addition, the results of the thrombin-induced release of labeled arachidonic acid pre-…

Blood Plateletsmedicine.medical_specialtyErythrocytesPlatelet AggregationThromboxaneRadioimmunoassayLipid peroxidationRats Sprague-Dawleychemistry.chemical_compoundThromboxane A2Internal medicineLipid biosynthesisThromboembolismmedicineAnimalsArachidonic AcidFibrinolysisThromboxanesUrokinase-Type Plasminogen ActivatorRecombinant ProteinsRatsThromboxane B2Disease Models AnimalOxidative StressEndocrinology12-Hydroxyheptadecatrienoic acidchemistryMacrophages Peritoneal12-Hydroxyeicosatetraenoic acidArachidonic acidFemaleLipid PeroxidationCardiology and Cardiovascular MedicineContraceptives OralAtherosclerosis
researchProduct

Anticoagulation in splanchnic and cerebral vein thrombosis: Still groping in the dark.

2020

Cerebral veinsmedicine.medical_specialtybusiness.industrymedicine.drug_classSplanchnic Circulation10031 Clinic for Angiology2720 HematologyAnticoagulantanticoagulantvenous thromboembolism610 Medicine & healthHematologyCerebral vein thrombosisbleedingcerebral veinsplanchnic circulationsInternal medicineCardiologyCommentaryMedicineDiseases of the blood and blood-forming organsRC633-647.5businessSplanchnicVenous thromboembolismResearch and practice in thrombosis and haemostasis
researchProduct

Diagnosis of pregnancy-associated venous thromboembolism - position paper of the Working Group in Women’s Health of the Society of Thrombosis and Hae…

2016

Venous thromboembolism (VTE) is a major cause of maternal morbidity during pregnancy and the postpartum period. However, because there is a lack of adequate study data, management strategies for pregnancy-associated VTE must be deduced from observational stu-dies and extrapolated from recommendations for non-pregnant patients. In this review, the members of the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH) have summarised the evidence that is currently available in the literature to provide a practical approach for treating pregnancy-associated VTE. Because heparins do not cross the placenta, weight-adjusted therapeutic-dose low molecular weight heparin …

Diagnostic Imagingmedicine.medical_specialtyConsensusmedicine.drug_classPregnancy Complications CardiovascularLow molecular weight heparinFibrin Fibrinogen Degradation ProductsPredictive Value of TestsPregnancyRisk FactorsHumansMedicinecardiovascular diseasesDosingIntensive care medicineVenous ThrombosisPregnancybusiness.industryWarfarinReproducibility of ResultsVenous Thromboembolismmedicine.diseasePulmonary embolismVenous thrombosisFemaleObservational studyPulmonary EmbolismCardiology and Cardiovascular MedicinebusinessBiomarkersPostpartum periodmedicine.drugVasa
researchProduct

Managing cancer patients with acute venous thromboembolism: exploring safe alternatives to hospitalisation

2004

Acute venous thromboembolism (VTE) is a common and potentially fatal complication that frequently occurs in cancer patients. Few data are currently available about the optimal management of this category of high-risk patients. In clinical practice, physicians have to deal with many problems related to cancer patients with acute VTE. For instance, cancer patients with deep vein thrombosis (DVT) are frequently admitted to the hospital since their high rate of recurrent thrombotic events and/or bleeding-related therapy; however, most of them would prefer alternatives to prolonged hospitalisation. Then, it is not clearly whether data coming from a non-cancer population (such as that regarding t…

Emergency careCancerVenous thromboembolism
researchProduct

Lungenembolie: Weniger Rezidive durch längere orale Antikoagulation

2015

Bei Patienten mit einer Lungenembolie reduziert eine Antikoagulation uber 3–6 Monate das Rezidivrisiko. Unklar ist bislang, ob dieser Effekt auch nach dem Ende der Therapie erhalten bleibt. Aktuell wurde der Nutzen einer zusatzlichen Behandlung mit Warfarin uber 18 Monate nach einer initalen 6-monatigen Therapie mit Vitamin-K-Antagonisten untersucht.

Gynecologymedicine.medical_specialtybusiness.industrymedicineWarfarinGeneral Medicinemedicine.diseasebusinessVenous thromboembolismCoronary heart diseasePulmonary embolismmedicine.drugDMW - Deutsche Medizinische Wochenschrift
researchProduct